← Back to Patent Explorer
US4563460A Expired / Lapsed US ⏱️ 0.0 years remaining

Quinoline and quinazoline derivatives for treating gastrointestinal motility dysfunctions

Assignee: William H Rorer Inc
•
Filing: 1984-01-13
•
Granted: 1986-01-07
•
Expires: 2004-01-13
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method for treating gastrointestinal motility dysfunctions using 2-amino-quinoline and -quinazoline derivatives.

Inventors

  • 👤 Donald E. Kuhla
  • 👤 William L. Studt
  • 👤 Henry F. Campbell
  • 👤 John Yelnosky

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 12:05
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/435; A61K31/47

Claims Analysis

Total Claims: 19
Claim 1
Independent Claim 95 words
A method for treating a patient suffering from a gastrointestinal motility dysfunction comprising medicating said patient with a therapeutically effective amount of a compound of the formula ##STR4## wherein: A is N or CH; X is oxygen, sulfur or NR 2 ; R 1 and R 2 are each independently hydrogen, alkyl, aryl, or aralkyl; R a , R b , R c and R d are each independently hydrogen or a phenyl substituent including halo, loweralkyl, haloloweralkyl, cyano, nitro, amino, mono- or di-loweralkylamino, lower alkoxy, hydroxy or benzyloxy; or a pharmaceutically acceptable salt thereof.
Claim 2
Independent Claim 95 words
A method for treating a patient suffering from a gastrointestinal motility dysfunction comprising medicating said patient with a therapeutically effective amount of a compound of the formula ##STR4## wherein: A is N or CH; X is oxygen, sulfur or NR 2 ; R 1 and R 2 are each independently hydrogen, alkyl, aryl, or aralkyl; R a , R b , R c and R d are each independently hydrogen or a phenyl substituent including halo, loweralkyl, haloloweralkyl, cyano, nitro, amino, mono- or di-loweralkylamino, lower alkoxy, hydroxy or benzyloxy; or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim 25 words
A method according to claim 1 wherein R a , R b and R c are hydrogen; and R d is hydrogen, loweralkyl or halo.
Claim 4
Dependent Claim 10 words
A method according to claim 1 wherein A is N.
Claim 5
Dependent Claim 17 words
A method according to claim 3 wherein: X is NH; and R 1 is hydrogen or loweralkyl.
Claim 6
Dependent Claim 24 words
A method according to claim 4 wherein: R a , R b and R c are hydrogen; and R d is loweralkyl or halo.
Claim 7
Dependent Claim 18 words
A method according to claim 3 wherein: X is O; and R 1 is phenyl or substituted phenyl.
Claim 8
Dependent Claim 32 words
A method according to claim 6 wherein: R 1 is phenyl substituted in at least one ortho position by halo, loweralkyl, haloloweralkyl, cyano, nitro, amino, mono- or di-alkylamino, alkoxy, hydroxy or benzyloxy.
Claim 9
Dependent Claim 32 words
A method according to claim 7 wherein R 1 is ##STR5## R a and R e are hydrogen, loweralkyl, or halo; provided that R a and R e are not both hydrogen.
Claim 10
Dependent Claim 7 words
A method according to claim 1 wherein:
Claim 11
Dependent Claim 17 words
A method according to claim 9 wherein X is O; R 1 is phenyl or substituted phenyl.
Claim 12
Dependent Claim 32 words
A method according to claim 10 wherein R 1 is phenyl substituted in at least one ortho position by halo, loweralkyl, haloloweralkyl, cyano, nitro, amino, mono- or dialkylamino, alkoxy, hydroxy or benzyloxy.
Claim 13
Dependent Claim 32 words
A method according to claim 11 wherein: R 1 is ##STR6## R a and R e are hydrogen, loweralkyl or halo; provided that R a and R e are not both hydrogen.
Claim 14
Dependent Claim 13 words
A method according to claim 12 wherein R 1 is 2,6-dimethylphenyl or 2,6-dichlorophenyl.
Claim 15
Dependent Claim 13 words
A method according to claim 8 wherein R 1 is 2,6-dimethylphenyl or 2,6-dichlorophenyl.
Claim 16
Dependent Claim 13 words
A method according to claim 1 for the treatment of irritable bowel syndrome.
Claim 17
Dependent Claim 52 words
A method for restoring to normal levels the intestinal function of a patient suffering from irritable bowel syndrome, comprising administering to said patient, one to eight times daily, a therapeutically effective oral or parenteral dose of about 0.5 to about 10 mg of a compound of the formula defined in claim 1.
Claim 18
Independent Claim 128 words
A method which is effective in treating irritable bowel syndrome characterized by the contemporaneous symptoms of constipation, diarrhea and abdominal pain comprising the daily medication of a patient suffering from irritable bowel syndrome with an amount of a compound which is effective in relieving said symptoms and/or preventing the onset of said symptoms, wherein said compound is of the formula: ##STR7## wherein: A is N or CH; X is oxygen, sulfur or NR 2 ; R 1 and R 2 are each independently hydrogen, alkyl, aryl, or aralkyl; R a , R b , R c and R d are each independently hydrogen or a phenyl substituent including halo, loweralkyl, haloloweralkyl, cyano, nitro, amino, mono- or di-loweralkylamino, lower alkoxy, hydroxy or benzyloxy; or a pharmaceutically acceptable salt thereof.
Claim 19
Independent Claim 128 words
A method which is effective in treating irritable bowel syndrome characterized by the contemporaneous symptoms of constipation, diarrhea and abdominal pain comprising the daily medication of a patient suffering from irritable bowel syndrome with an amount of a compound which is effective in relieving said symptoms and/or preventing the onset of said symptoms, wherein said compound is of the formula: ##STR7## wherein: A is N or CH; X is oxygen, sulfur or NR 2 ; R 1 and R 2 are each independently hydrogen, alkyl, aryl, or aralkyl; R a , R b , R c and R d are each independently hydrogen or a phenyl substituent including halo, loweralkyl, haloloweralkyl, cyano, nitro, amino, mono- or di-loweralkylamino, lower alkoxy, hydroxy or benzyloxy; or a pharmaceutically acceptable salt thereof.

References Cited (Backward Citations)

US4293549A Cited
US4266062A Cited
US4239768A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1989-01-06 1989-07-08 1990-01-07 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1993-01-06 1993-07-08 1994-01-07 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1997-01-06 1997-07-08 1998-01-07 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag